Company profile
Pulmocide
Developing best-in-class inhaled medicines for targeted treatment of life-threatening respiratory diseases.
- Industry
- Biotechnology Research
- Employees
- 19
- Headquarters
- London
- Founded
- 2013
- Office locations
- 3
Pulmocide company summary
Pulmocide is a company in the Biotechnology Research industry, headquartered in London, founded in 2013. On LinkedIn the company has around 19 employees. The company lists 3 office locations. Its listed specialties include Severe respiratory diseases, Inhaled therapeutics, Pulmonary aspergillosis, Pharmaceuticals, Acute and chronic lung infections.
What technology does Pulmocide use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Pulmocide
Pulmocide is a biopharmaceutical company that specializes in tackling difficult-to-treat respiratory diseases. We focus on respiratory fungal infections that can be serious and life-threatening and have significant effects on patients’ quality of life. Our current clinical development focus is on treating patients who have not successfully responded to the standard of care and on the prophylactic treatment of lung transplant patients. Pulmocide’s innovative approach to drug development provides a novel potential therapy that has been specifically designed to treat the most common fungal lung disease, pulmonary aspergillosis. Opelconazole was designed for inhaled delivery to minimize systemic exposure and deliver a high concentration of drug with a long retention time at the site of infection. This approach could improve treatment outcomes in patients with fungal lung disease without increasing systemic side effects and without interactions with other medications. The Pulmocide team is well experienced in the discovery and development of inhaled therapies for respiratory and infectious disease indications. They have particular expertise in the identification of novel compounds that can be delivered directly to the lungs.
Specialties
Where is Pulmocide located?
Pulmocide lists 3 office locations.
Compare companies similar to Pulmocide
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Pulmocide pulmocide.com | Biotechnology Research | 19 | 2013 | London |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Pulmocide
What does Pulmocide do?
Pulmocide is a biopharmaceutical company that specializes in tackling difficult-to-treat respiratory diseases. We focus on respiratory fungal infections that can be serious and life-threatening and have significant effects on patients’ quality of life. Our current clinical development focus is on treating patients who have not successfully responded to the standard of care and on the prophylactic treatment of lung transplant patients. Pulmocide’s innovative approach to drug development provides a novel potential therapy that has been specifically designed to treat the most common fungal lung disease, pulmonary aspergillosis. Opelconazole was designed for inhaled delivery to minimize systemic exposure and deliver a high concentration of drug with a long retention time at the site of infection. This approach could improve treatment outcomes in patients with fungal lung disease without increasing systemic side effects and without interactions with other medications. The Pulmocide team is well experienced in the discovery and development of inhaled therapies for respiratory and infectious disease indications. They have particular expertise in the identification of novel compounds that can be delivered directly to the lungs.
How many employees does Pulmocide have?
Pulmocide has around 19 employees on LinkedIn.
Where is Pulmocide headquartered?
Pulmocide is headquartered in London.
Where does Pulmocide have offices?
Pulmocide lists 3 office locations, including London, GB, GB; Boston, US, US; United Kingdom, GB, GB.
When was Pulmocide founded?
Pulmocide was founded in 2013.
Build a lead list from companies like Pulmocide
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.